$26.52
5.86% yesterday
Nasdaq, Jun 27, 10:11 pm CET
ISIN
US92686J1060
Symbol
VKTX
Sector
Industry

Viking Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation

Viking Therapeutics, Inc. Classifications & Recommendation:

Buy
88%
Hold
12%

Viking Therapeutics, Inc. Price Target

Target Price $103.02
Price $26.52
Potential
Number of Estimates 19
19 Analysts have issued a price target Viking Therapeutics, Inc. 2026 . The average Viking Therapeutics, Inc. target price is $103.02. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 25 analysts: 22 Analysts recommend Viking Therapeutics, Inc. to buy, 3 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Viking Therapeutics, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Viking Therapeutics, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Dec '24 2025
Estimates
Earnings Per Share $ -1.01 -1.93
10.99% 91.09%
P/E negative
EV/Sales 1,417.73

21 Analysts have issued a Viking Therapeutics, Inc. forecast for earnings per share. The average Viking Therapeutics, Inc. EPS is

$-1.93
Unlock
. This is
67.83% lower
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$-1.55 34.78%
Unlock
, the lowest is
$-2.52 119.13%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-1.01 10.99%
2025
$-1.93 91.09%
Unlock
2026
$-2.62 35.75%
Unlock
2027
$-3.04 16.03%
Unlock
2028
$-2.70 11.18%
Unlock
2029
$-1.06 60.74%
Unlock
2030
$2.89 372.64%
Unlock
2031
$8.20 183.74%
Unlock
2032
$13.38 63.17%
Unlock

P/E ratio

Current -23.06 60.65%
2025
-13.76 40.33%
Unlock
2026
-10.12 26.45%
Unlock
2027
-8.72 13.83%
Unlock
2028
-9.81 12.50%
Unlock
2029
-25.04 155.25%
Unlock
2030
9.18 136.66%
Unlock
2031
3.23 64.81%
Unlock
2032
1.98 38.70%
Unlock

Current Viking Therapeutics, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Jun 25 2025
Cantor Fitzgerald
Locked
Locked
Locked Apr 28 2025
Truist Securities
Locked
Locked
Locked Apr 28 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 24 2025
Morgan Stanley
Locked
Locked
Locked Apr 24 2025
HC Wainwright & Co.
Locked
Locked
Locked Apr 17 2025
Goldman Sachs
Locked
Locked
Locked Apr 08 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 25 2025
Locked
Cantor Fitzgerald:
Locked
Locked
Apr 28 2025
Locked
Truist Securities:
Locked
Locked
Apr 28 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 24 2025
Locked
Morgan Stanley:
Locked
Locked
Apr 24 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Apr 17 2025
Locked
Goldman Sachs:
Locked
Locked
Apr 08 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today